Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present six oral and three poster presentations at the 65th American Society of Hematology (ASH) Meeting & Exposition, occurring in San Diego, California and virtually December 9-12, 2023. The presentations focus on treatments for acute leukemias and lymphomas.
Among the data are the promising results of the phase 2 PrE0405 trial, which evaluated bendamustine, rituximab, and venetoclax for the initial treatment of mantle cell lymphoma in older patients. Other abstracts are secondary analyses from the practice-changing E1910 phase 3 trial (Abstract LBA-1 at ASH 2022). Details for the nine presentations are below, listed by type and date.
Oral Presentations
-
The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia
Presenter: Satoshi Yoshimura, MD (St. Jude Children's Research Hospital)
Date and Time: Sunday, December 10, 4:45 PM
Location: Grand Hall D, Manchester Grand Hyatt San Diego
Abstract 596 in Session 618 (entire session 4:30-6:00 PM) -
Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN E2906 Phase 3 Trial
Presenter: James M. Foran, MD (Mayo Clinic Florida)
Date and Time: Sunday, December 10, 5:45 PM
Location: Pacific Ballroom Salons 24-26, Marriott Marquis San Diego Marina
Abstract 594 in Session 613 (entire session 4:30-6:00 PM) -
Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age (PrE0405)
Presenter: Craig A. Portell, MD (University of Virginia Medical Center)
Date and Time: Monday, December 11, 10:30 AM
Location: Grand Hall B, Manchester Grand Hyatt San Diego
Abstract 733 in Session 623 (entire session 10:30 AM-12:00 PM) -
Single Cell Transcriptomic Analysis of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Reveals Correlation between Leukemia Cell State, Genetic Alterations and Clinical Outcome
Presenter: Ilaria Iacobucci, PhD (St. Jude Children's Research Hospital)
Date and Time: Monday, December 11, 2:45 PM
Location: Grand Hall D, Manchester Grand Hyatt San Diego
Abstract 841 in Session 618 (entire session 2:45-4:15 PM) -
STAG2/LMO2 Gamma-Delta (γÎ') T-Cell Acute Lymphoblastic Leukemia: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young
Presenter: Shunsuke Kimura, MD, PhD (St. Jude Children's Research Hospital)
Date and Time: Monday, December 11, 3:45 PM
Location: Grand Hall D, Manchester Grand Hyatt San Diego
Abstract 845 in Session 618 (entire session 2:45-4:15 PM) -
Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)
Presenter: Catherine S. Diefenbach, MD (Perlmutter Cancer Center at NYU Langone Health)
Date and Time: Sunday, December 10, 4:30 PM
Location: Grand Hall B, Manchester Grand Hyatt San Diego
Abstract 607 in Session 624 (entire session 4:30-6:00 PM)
Poster Presentations
-
Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
Presenter: Selina M. Luger, MD, FRCPC (University of Pennsylvania)
Date and Time: Sunday, December 10, 6:00-8:00 PM
Location: Halls G-H, San Diego Convention Center
Abstract 2877 in Session 614 -
AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Presenter: Tara O. Henderson, MD (University of Chicago Medical Center)
Date and Time: Sunday, December 10, 6:00-8:00 PM
Location: Halls G-H, San Diego Convention Center
Abstract 3084 in Session 624
ECOG-ACRIN participated in this trial through a collaboration across the National Cancer Institute's National Clinical Trials Network (NCTN). -
A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged Acute Myeloid Leukemia Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999
Presenter: Yaseswini Neelamraju (University of Virginia)
Date and Time: Monday, December 11, 6:00-8:00 PM
Location: Halls G-H, San Diego Convention Center
Abstract 4326 in Session 617
Presenters are available for media interviews under the ASH news embargo policy.
About ECOG-ACRIN
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. The Group comprises nearly 1300 member institutions and 15,000 research professionals in the United States and around the world. It is funded primarily by the National Cancer Institute, part of the National Institutes of Health. Visit ecog-acrin.org, and follow us on Twitter @eaonc, Facebook, and LinkedIn.
About PrECOG
The PrECOG, LLC cancer research organization designs and conducts innovative oncology studies through industry partnerships and research networks. Its current portfolio includes phase 1 and 2 multi-center trials and US-based and multi-national phase 3 trials. The central focus of PrECOG is to conduct trials that align with the overall scientific mission and research goals of the ECOG-ACRIN Cancer Research Group. Visit www.precogllc.org and follow us on Twitter @PrECOGonc, Facebook, and LinkedIn.